Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 16, 2016 - Issue 9
Submit an article Journal homepage
531
Views
21
CrossRef citations to date
0
Altmetric
Review

Third generation antiepileptic drug monotherapies in adults with epilepsy

Marco MulaAtkinson Morley Regional Neuroscience Centre, St George’s University Hospitals NHS Foundation Trust, London, UK;Department of Neuropsychiatry, South West London & St George’s Mental Health Trust, London, UK;Institute of Medical and Biomedical Sciences, St George’s University of London, London, UKCorrespondence[email protected]
Pages 1087-1092 | Received 31 Mar 2016, Accepted 25 May 2016, Published online: 08 Jun 2016

References

  • Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology. 2011;77(10):1005–1012.
  • Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
  • Patsalos PN, Berry DJ. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Expert Opin Pharmacother. 2012;13(5):699–715.
  • Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–1120.
  • Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563.
  • Keating GM. Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures. CNS Drugs. 2014;28(7):583–600.
  • Jacobson MP, Pazdera L, Bhatia P, et al. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurol. 2015;15:46.
  • Sperling MR, Harvey J, Grinnell T, et al.; 045 Study Team. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Epilepsia. 2015;56(4):546–555.
  • Sperling MR, French J, Jacobson MP, et al. Conversion to eslicarbazepine acetate monotherapy: a pooled analysis of 2 phase III studies. Neurology. 2016;86(12):1095–1102.
  • Hoy SM. Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures. CNS Drugs. 2013;27(12):1125–1142.
  • Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55(7):1088–1098.
  • Lattanzi S, Cagnetti C, Foschi N, et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71–74.
  • Giráldez BG, Toledano R, García-Morales I, et al. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: a multicenter evaluation. Seizure. 2015;29:119–122.
  • Mula M. Brivaracetam for the treatment of epilepsy in adults. Expert Rev Neurother. 2014;14(4):361–365.
  • Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–1015.
  • Cross H, Ferrie C, Lascelles K, et al. Old versus new antiepileptic drugs: the SANAD study. Lancet. 2007;370(9584):314.
  • Panayiotopoulos CP. Old versus new antiepileptic drugs: the SANAD study. Lancet. 2007;370(9584):313–314.
  • Perucca E, Alexandre V, Tomson T. Old versus new antiepileptic drugs: the SANAD study. Lancet. 2007;370(9584):313.
  • Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008;70(1):54–65.
  • Brodie MJ, Barry SJE, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554.
  • Mula M. Recent and future antiepileptic drugs and their impact on cognition: what can we expect? Expert Rev Neurother. 2012;12(6):667–671.
  • Mula M, Cock HR. More than seizures: improving the lives of people with refractory epilepsy. Eur J Neurol. 2015;22(1):24–30.
  • Mintzer S, French JA, Perucca E, et al. Is a separate monotherapy indication warranted for antiepileptic drugs? Lancet Neurol. 2015;14(12):1229–1240.
  • Eichler H-G, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther. 2012;91(3):426–437.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.